Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Effects of nafarelin on bone density.

J B Jacobson1

  • 1Department of Obstetrics and Gynecology, Södertälje Hospital, Sweden.

American Journal of Obstetrics and Gynecology
|February 1, 1990
PubMed
Summary

Nafarelin use for endometriosis can affect bone metabolism. High doses decreased bone mineral density, but levels normalized after stopping treatment. Combination therapy with norethindrone showed no significant bone loss.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thymic lymphocytes. III. Cooperative phenomenon in the proliferation of thymocytes under Con A stimulation.

Cellular immunology·1986
Same author

A new vaginal antifungal agent--butoconazole nitrate.

Acta obstetricia et gynecologica Scandinavica·1985
Same author

Second-trimester spontaneous regression of theca lutein cysts.

Obstetrics and gynecology·1982
Same author

Retroperitoneal hemorrhage during pregnancy secondary to renal angiomyolipoma.

Urologic radiology·1982
Same author

Management of the fetus with a urinary tract malformation.

JAMA·1981
Same author

The transverse common duct.

AJR. American journal of roentgenology·1981

Area of Science:

  • Reproductive Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Endometriosis affects premenopausal women, impacting quality of life.
  • Gonadotropin-releasing hormone (GnRH) analogs are used to treat endometriosis.
  • The impact of GnRH analogs on bone metabolism requires careful evaluation.

Purpose of the Study:

  • To assess the effects of nafarelin, a GnRH analog, on bone metabolism in premenopausal women with endometriosis.
  • To compare the effects of different nafarelin dosages on bone mineral density and resorption.
  • To evaluate bone mineral recovery after nafarelin treatment cessation.

Main Methods:

  • Two studies were conducted, each involving 6 months of nafarelin treatment followed by 6 months of observation.
  • Bone mineral measurements and bone resorption markers were assessed.
  • A second study compared nafarelin with norethindrone combination therapy.

Main Results:

  • Low-dose nafarelin (200 mcg/day) maintained bone mineral measurements.
  • High-dose nafarelin (400 mcg/day) led to significant decreases in bone mineral levels and increased bone resorption.
  • Bone mineral levels and resorption returned to baseline within 6 months after discontinuing nafarelin.
  • Combination therapy with nafarelin (400 mcg/day) and norethindrone (1.2 mg/day) did not result in significant bone mineral loss.

Conclusions:

  • Nafarelin's effect on bone metabolism is dose-dependent.
  • Bone mineral density loss associated with high-dose nafarelin is reversible upon treatment cessation.
  • Combination therapy with norethindrone may mitigate bone loss during endometriosis treatment.

Related Experiment Videos